Stocks / NASDAQ / Cellectis S.A.

Cellectis S.A.

Industry:   Health Care - Biotechnology: Biological Products (No Diagnostic Substances) Stock Symbol:   CLLS - NASDAQ Animal Usage:   Animal Testing

Our Opinion

Cellectis S.A. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

Press release: Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models.

Company Description

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through its business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France. [Source: MarketWatch]

Company Website: http://www.cellectis.com

Contact:   http://www.cellectis.com/en/content/contact; IR: http://www.cellectis.com/en/investor-contact;